A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis

Journal of Experimental Medicine

Volumn 200, Issue 11, 2004, Pages 1419-1426

  Gibot, Sébastien ^a,b   Kolopp Sarda, Marie Nathalie ^b   Béné, Marie C ^b   Bollaert, Pierre Edouard ^a   Lozniewski, Alain ^a   Mory, Françoise ^a   Levy, Bruno ^a,b   Faure, Gilbert C ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Inflammation; Mouse model; Proinflammatory cytokines; Sepsis; Triggering receptor expressed on myeloid cells 1

Indexed keywords

LIPOPOLYSACCHARIDE; SYNTHETIC PEPTIDE;

ARTICLE; ATTENUATION; BONE MARROW CELL; CELL SECRETION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEATH; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CYTOKINES; ENDOTOXEMIA; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; SEPSIS;

EID: 10644237032     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20040708     Document Type: Article

References (34)

1. Aderem, A, and R.J. Ulevitch, R.J. 2000. Toll-like receptors in the induction of the innate immune response. Nature. 406: 782-786.
2. Thoma-Uszynski, S., S. Stenger, O. Takeuchi, M.T. Ochoa, P.A. Engele, P.A. Sieling, P.F. Barnes, M. Rollinghoff, P.L. Bolcskei, and M. Wagner. 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science. 291:1544-1549.
3. Medzhitov, R., and C. Janeway Jr. 2000. Innate immunity. N. Engl. J. Med. 343:338-344.
4. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature. 420:885-891.
5. Hotchkiss, R.S., and I.E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138-150.
6. Vincent, J.L., Q. Sun, and M.J. Dubois. 2002. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34:1084-1093.
7. Riedemann, N.C., R.F. Guo, and P. Ward. 2003. Novel strategies for the treatment of sepsis. Nat. Med. 9:517-524.
8. Fisher, C.J., Jr., J.M. Agosti, S.M. Opal, S.F. Lowry, R.A. Balk, J.C. Sadoff, E. Abraham, R.M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The soluble TNF receptor sepsis study group. N. Engl. J. Med. 334:1697-1702.
9. Echtenacher, B., W. Falk, D.N. Mannel, and P.H. Krammer. 1990. Requirement of endogenous tumor necrosis factor/ cachectin for recovery from experimental peritonitis. J. Immunol. 145:3762-3766.
10. Echtenacher, B., K. Weigl, N. Lehn, and D.N. Mannel. 2001. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect. Immun. 69:3550-3555.
11. Eskandari, M.K., G. Bolgos, C. Miller, D.T. Nguyen, L.E. DeForge, and D.G. Remick. 1992. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148:2724-2730.
12. Bouchon, A., J. Dietrich, and M. Colonna. 2000. Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164:4991-4995.
13. Colonna, M., and F. Facchetti. 2003. TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. J. Infect. Dis. 187:S397-S401.
14. Colonna, M. 2003. TREMs in the immune system and beyond. Nat. Rev. Immunol. 3:445-453.
15. Nathan, C., and A. Ding. 2001. TREM-1: a new regulator of innate immunity in sepsis syndrome. Nat. Med. 7:530-532.
16. Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 410:1103-1107.
17. Bleharski, J.R., V. Kiessler, C. Buonsanti, P.A. Sieling, S. Stenger, M. Colonna, and R.L. Modlin. 2003. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J. Immunol. 170:3812-3818.
18. Gibot, S., A. Cravoisy, B. Levy, M.C. Béné, G. Faure, and P.E. Bollaert. 2004. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N. Engl. J. Med. 350:451-458.
19. Gingras, M.C., H. Lapillonne, and J.F. Margolin. 2002. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol. Immunol. 38: 817-824.
20. Dinarello, C.A. 1997. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 112:S321-S329.
21. Bone, R.C. R.A Balk, F.B. Cerra, R.P. Dellinger, A.M. Fein, W.A. Knauss, R.M. Schein, and W.J. Sibbald. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 101:1644-1655.
22. Warren, H.S. 1997. Strategies for the treatment of sepsis. N. Engl. J. Med. 336:952-953.
23. Stone, R. 1994. Search for sepsis drugs goes on despite past failures. Science. 264:365-367.
24. Cohen, J. 2001. TREM-1 in sepsis. Lancet. 358:776-778.
25. Begum, N.A., K. Ishii, M. Kurita-Taniguchi, M. Tanabe, M. Kobayashi, Y. Moriwaki, M. Matsumoto, Y. Fukumori, I. Azuma, K. Toyoshima, and T. Seya. 2004. Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA substraction in human macrophages. Infect. Immun. 72:937-948.
26. Keane, J., S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman, J.N. Siegel, and M.M. Braun. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345: 1098-1104.
27. Radaev, S., M. Kattah, B. Rostro, M. Colonna, and P. Sun. 2003. Crystal structure of the human myeloid cell activating receptor TREM-1. Structure. 11:1527-1535.
28. Lantz, M., U. Gullberg, and E. Nilsson. 1990. Characterization in vitro of a human tumor necrosis factor binding protein. A soluble form of tumor necrosis factor receptor. J. Clin. Invest. 86:1396-1401.
29. van Zee, K.J., T. Kohno, and E. Fischer. 1992. Tumor necrosis soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 89:4845-4853.
30. Collart, M.A., P. Baeuerle, and P. Vassalli. 1990. Regulation of tumor necrosis factor alpha transcription in macrophages. Involvement of four NFκB motifs and constitutive and inducible form of NFκB. Mol. Cell. Biol. 10:1498-1506.
31. Hiscott, J.M., J.J. Garoufalis, A. Roulston, I. Kwan, N. Pepin, J. Lacoste, H. Nguyen, G. Bensi, and M. Fenton. 1993. Characterization of a functional NFκB site in the human IL-1β promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 13:6231-6240.
32. Urban, M.B., R. Schreck, and P.A. Baeuerle. 1991. NFκB contacts DNA by a heterodimer of the p50 and p65 subunit. EMBO J. 10:1817-1825.
33. Lolis, E., and R. Bucala. 2003. Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat. Rev. Drug Discov. 2:635-645.
34. Gibot, S., M.N. Kolopp-Sarda, M.C. Béné, A. Cravoisy, B. Levy, G. Faure, and P.E. Bollaert. 2004. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann. Intern. Med. 141:9-15.